#1 Clinical Trials Search in Europe

Dnth103

DNTH103 is an investigational drug currently being studied in clinical trials for the treatment of two neurological conditions: Multifocal Motor Neuropathy (MMN) and Generalized Myasthenia Gravis (gMG). These Phase 2 studies aim to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in adult patients. The trials involve randomized, double-blinded, placebo-controlled designs to thoroughly assess the potential benefits and risks of this new treatment option.

Table of Contents

What is DNTH103?

DNTH103 is a new medication currently being studied for its potential to treat certain neurological disorders[1][2]. It is still in the experimental stage and is not yet approved for general use. Researchers are conducting clinical trials to determine if DNTH103 is safe and effective for patients with specific nerve and muscle conditions.

What Conditions Does DNTH103 Treat?

DNTH103 is being investigated for two main conditions:

  • Multifocal Motor Neuropathy (MMN): This is a rare condition that affects the nerves controlling muscle movement, primarily in the arms and legs. It can cause weakness and muscle wasting over time[1].
  • Generalized Myasthenia Gravis (gMG): This is an autoimmune disorder that causes muscle weakness and fatigue throughout the body. The term “generalized” means it affects multiple muscle groups[2].

Both of these conditions can significantly impact a person’s daily life and ability to perform routine tasks.

How is DNTH103 Administered?

Based on the clinical trial information, DNTH103 is given to patients in the following way[1][2]:

  1. On the first day of treatment (Day 1), patients receive an intravenous (IV) loading dose. This means the medication is given directly into a vein.
  2. After the initial dose, DNTH103 is administered subcutaneously (SC) every two weeks. Subcutaneous means the medication is injected just under the skin.

The treatment schedule varies slightly between the two studies:

  • For MMN, treatment continues from Week 1 to Week 15[1].
  • For gMG, treatment is given from Week 1 to Week 11[2].

Current Clinical Trials

DNTH103 is currently being studied in two Phase 2 clinical trials:

  1. MOMENTUM Study: This trial is evaluating DNTH103 in adults with Multifocal Motor Neuropathy (MMN)[1].
  2. MAGIC Study: This trial is testing DNTH103 in adults with Generalized Myasthenia Gravis (gMG)[2].

Both studies are designed as randomized, double-blinded, and placebo-controlled trials. This means that participants are randomly assigned to receive either DNTH103 or a placebo (a substance with no active medication), and neither the participants nor the researchers know who is receiving which treatment during the study. This design helps ensure that the results are not influenced by expectations or bias.

Safety and Side Effects

A primary goal of both clinical trials is to assess the safety and tolerability of DNTH103. Researchers are closely monitoring[1][2]:

  • Treatment-emergent adverse events (TEAEs): These are any unfavorable medical occurrences that happen after starting the treatment, whether they’re related to the medication or not.
  • Serious adverse events (SAEs): These are more severe side effects that may require medical intervention.
  • Changes in ECG parameters: This involves monitoring the electrical activity of the heart to ensure the medication doesn’t cause any cardiac issues.
  • Changes in clinical laboratory values: This includes regular blood tests to check for any effects on various body systems.

The studies also look at adverse events of special interest (AESI), which are specific side effects that the researchers are particularly watchful for based on what they know about the medication[2].

How Effectiveness is Measured

To determine if DNTH103 is working, researchers use various tools and measurements[1][2]:

  • Grip strength: Measured using a device called a vigorimeter, this shows how the medication affects muscle strength in the hands.
  • Medical Research Council (MRC) scores: These evaluate muscle strength in different parts of the body.
  • Disability scales: Such as the MMN-RODS for neuropathy and the MG-ADL for myasthenia gravis, these assess how the conditions affect daily activities.
  • Quality of life measures: Including questionnaires about fatigue, overall health status, and treatment satisfaction.
  • Specific tests: Like the 9-Hole Peg Test, which measures hand dexterity.

For patients with MMN, researchers also track how long patients can go without needing their usual immunoglobulin treatments[1].

Future Prospects for DNTH103

As DNTH103 is still in Phase 2 clinical trials, it’s too early to say definitively how effective it will be or when it might become available to patients outside of research studies. However, these trials are crucial steps in the drug development process[1][2].

If the results from these studies are promising, DNTH103 may move on to larger Phase 3 trials. Successful completion of all clinical trial phases could eventually lead to the medication being approved for use in patients with MMN or gMG.

It’s important for patients with these conditions to stay informed about new treatments in development, but also to remember that it can take several years for a new medication to complete all necessary studies and potentially become available for general use.

Aspect MMN Study (MOMENTUM) gMG Study (MAGIC)
Study Phase Phase 2 Phase 2
Study Design Randomized, Double-Blinded, Placebo-Controlled Randomized, Blinded, Placebo-Controlled
Treatment Duration 16 weeks (Day 1 to Week 15) 12 weeks (Day 1 to Week 11)
Primary Outcome Timeframe Baseline to Week 17 Baseline to Week 13
DNTH103 Administration IV loading dose, then SC every 2 weeks IV loading dose, then SC every 2 weeks
Key Efficacy Measures Grip strength, MRC scores, MMN-RODS MG-ADL scale, QMG scale
Safety Assessments TEAEs, SAEs TEAEs, AESIs, ECG changes, lab values

FAQ

  • What is DNTH103? DNTH103 is an investigational drug being studied for the treatment of Multifocal Motor Neuropathy (MMN) and Generalized Myasthenia Gravis (gMG). It is administered through intravenous (IV) loading doses followed by subcutaneous (SC) injections every two weeks.
  • What conditions are being studied with DNTH103? DNTH103 is currently being studied in clinical trials for two neurological conditions: Multifocal Motor Neuropathy (MMN) and Generalized Myasthenia Gravis (gMG).
  • How is DNTH103 administered in the clinical trials? In both trials, DNTH103 is administered with an initial intravenous (IV) loading dose on Day 1, followed by subcutaneous (SC) injections every two weeks for the duration of the study period.
  • What are the main outcomes being measured in these trials? The primary outcomes focus on the safety and tolerability of DNTH103, including the incidence of treatment-emergent adverse events. Secondary outcomes measure the drug's effectiveness using various disease-specific scales, such as grip strength for MMN and the MG-ADL scale for gMG, as well as quality of life measures.
  • How long do these clinical trials last? The MMN study (MOMENTUM) lasts for 17 weeks, while the gMG study (MAGIC) has a primary assessment period of 13 weeks, with safety follow-up continuing up to 40 weeks.

Ongoing Clinical Trials on Dnth103

  • Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

    Recruiting

    1 1
    Investigated drugs:
    Belgium Bulgaria Croatia Denmark France Germany +6

  • Study on the Safety and Effects of DNTH103 for Adults with Multifocal Motor Neuropathy

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Denmark France Italy The Netherlands Poland Spain

  • Study on the Safety and Tolerability of DNTH103 for Adults with Generalized Myasthenia Gravis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Italy The Netherlands Norway +3

Glossary

  • Multifocal Motor Neuropathy (MMN): A rare neurological disorder characterized by progressive muscle weakness and atrophy, typically affecting the arms more than the legs.
  • Generalized Myasthenia Gravis (gMG): An autoimmune disorder causing muscle weakness and fatigue, affecting multiple muscle groups throughout the body.
  • Pharmacometrics: The science of developing and applying mathematical and statistical methods to characterize, understand, and predict a drug's behavior in the body.
  • Placebo: An inactive substance or treatment that looks like the drug being tested but has no medical effect.
  • Double-blinded: A study design where neither the participants nor the researchers directly involved know who is receiving the actual treatment and who is receiving a placebo.
  • Subcutaneous (SC): A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Treatment-emergent adverse events (TEAEs): Any unfavorable and unintended sign, symptom, or disease that appears or worsens after starting a medical treatment.
  • Antidrug antibody (ADA): Antibodies produced by the body's immune system in response to a therapeutic drug, which may affect the drug's effectiveness or safety.
  • MG-ADL scale: Myasthenia Gravis Activities of Daily Living scale, a patient-reported outcome measure used to assess the impact of MG on daily activities.
  • QMG scale: Quantitative Myasthenia Gravis scale, a tool used to measure the severity of muscle weakness in MG patients.
  • Vigorimeter: A device used to measure grip strength, often used in assessing patients with neurological conditions affecting hand function.

References